Current treatment of psoriatic arthritis

Rheumatic Disease Clinics of North America

Volumn 29, Issue 3, 2003, Pages 495-511

  Mease, Philip J ^a,b  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETORICOXIB; GOLD; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; MONOCLONAL ANTIBODY CD3; NONSTEROID ANTIINFLAMMATORY AGENT; OM 89; ONERCEPT; PREDNISONE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT TUMOR NECROSIS FACTOR BINDING PROTEIN 2; ROFECOXIB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR BINDING PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

CLINICAL TRIAL; DEMYELINATING DISEASE; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; GENETIC DISORDER; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; TUBERCULOSIS;

EID: 0042522553     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00047-4     Document Type: Review

References (93)

1. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27(5):1247-50.
2. Brockbank J, Schentag CT, Rosen C, Gladman DD. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medicine clinic attendees [abstract 249]. Arthritis Rheum 2001;44(Suppl 9):S94.
3. Gladman DD. Psoriatic arthritis. In: Maddison PJ, Isenberg DA, Glass DN, editors. Oxford textbook of rheumatology. Oxford: Oxford University Press; 1998. p. 1071-84.
4. Salvarani C, Lo SG, Macchioni P, Cremonesi T, Rossi F, Mantovani W, et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol 1995;22(8):1499-503.
5. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Vital Health Statistics 1999;10(200):1-212.
6. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3(1):55-78.
7. Sege-Peterson K, Winchester R. Psoriatic arthritis. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al, editors. Fitzpatrick's dermatology in general medicine. New York: McGraw-Hill; 1999. p. 522-33.
8. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 2000;9(7):1511-22.
9. Gladman DD, Stafford-Brady F, Chang C-H, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17(6):809-12.
10. Torre Alonso JC, Rodriguez PA, Arribas Castrillo JM, Ballina GJ, Riestra Noriega JL, Lopez LC. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991;30(4):245-50.
11. Rahman P, Gladman DD, Cook RJ, Zhou, Young G, Salonen D. Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998;37(7):760-5.
12. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41(6): 1103-10.
13. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40(10): 1868-72.
14. McGonagle D, Gibbon W, Emery P. Classification ofinflammatory arthritis by enthesitis. Lancet 1998;352(9134):1137-40.
15. Bukulmez H, Dunn RS, Pratt RG, Dardzinski BJ, Colbert RA. Magnetic resonance imaging (MRI) in HLA-B27 transgenic rat model of spondyloarthropathy: image findings prior to clinically detectable arthritis [abstract 982]. Arthritis Rheum 2002;46(Suppl 9):S380.
16. Braun J, Barakiakos X, Golder W, Listing J, Brandt J, Bollow M, et al. Ankylosing spondylitis (AS) - development and evaluation of a spinal scoring system (ASspiMRI) using magnetic resonance imaging (MRI) in patients with active disease [abstract 114]. Arthritis Rheum 2002;46(Suppl 9):S426.
17. Braun J, Barakiakos X, Golder W, Listing J, Brandt J, Bollow M, et al. Improvement of spinal inflammation in ankylosing spondylitis (AS) by infliximab therapy as assessed by a magnetic resonance imaging (MRI) using a novel evaluated spinal scoring system - results of a doubleb-lind, placebo-controlled trial [abstract 115]. Arthritis Rheum 2002;46(Suppl 9):S426-7.
18. Klauser A, Springer P, Frauscher F, Schirmer M. Comparison between magnetic resonance imaging, unenhanced and contrast-enhanced ultrasound in the diagnosis of active sacroiliitis [abstract 113]. Arthritis Rheum 2002;46(Suppl 9):S426.
19. Kamel M, Mansour R, Eid H, Fernandez I. Ultrasound detection of patellar enthesitis: a comparison with MRI [abstract 177]. Arthritis Rheum 2002;46(Suppl 9): S104.
20. Alcalde M, Cruz M, Bordoy C, González L, Acebes C, Sánchez-Pernaute O, et al. Assessment of entheseal injury in ankylosing spondylitis by ultrasound [abstract 1117]. Arthritis Rheum 2002;46(Suppl 9):S427.
21. Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;38:618-27.
22. Melian A, Van der Heijde D, James MK, Calin A, Giallella KM, Reicin AS, et al. Etoricoxib in the treatment of ankylosing spondylitis (AS) [abstract 1131]. Arthritis Rheum 2002;46(Suppl 9):S432.
23. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995;22(4):675-9.
24. Christophers E, Mrowietz U. Psoriasis. In: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Fitzpatrick's dermatology in general medicine. 5th edition. New York: McGraw Hill; 1999. p. 495-521.
25. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc 2001;76:943-9.
26. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review). Oxford: The Cochrane Library; 2001.
27. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27(4):376-81.
28. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995;22:241-55.
29. Lacaille D, Stein HB, Raboud J, Klinkhoff AV. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol 2000;27(8):1922-7.
30. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13(5):589-93.
31. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28(10):2274-82.
32. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department ot Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39(12):2013-20.
33. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study, Arthritis Rheum 1999;42(11):2325-9.
34. Combe B, Goupille P, Kuntz JL, Tebib J, Liota F, Bregeon C. Sulfasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 1996;35(7):664-8.
35. Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38(5):618-27.
36. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995;22(5): 894-8.
37. Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulfasalazine in the management of psoriatic arthritis. Br J Rheumatol 1993;32(10):923-5.
38. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990;29:46-9.
39. Hopkins R, Bird HA, Jones H, Hill J, Surrall KE, Astbury C, et al. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis 1985;44(3):189-93.
40. Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990;29(4):280-3.
41. Matucci-Cerinic M, Pignone A, Lotti T, Partsch G, Livi R, Cagnoni M. Gold salts and somatostatin: a new combined analgesic treatment for psoriatic arthritis. Drugs Exp Clin Res 1992;18(2): 53-61.
42. Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthriris. J Rheumatol 1992;19(11):1724-6.
43. Sayers ME, Mazanec DJ. Use of antimalarial drugs for the treatment of psoriatic arthritis. Am J Med 1992;93(4):474-5.
44. Vine JE, Hymes SR, Warner NB, Cohen PR. Pustular psoriasis induced by hydroxychloroquine: a case report and review of the literature. J Dermatol 1996;23(5):357-61.
45. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999;455:221-5.
46. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343(22):1586-93.
47. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46(6):1443-50.
48. Bondeson J, Maini RN. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int J Clin Pract 2001;55(3):211 -6.
49. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86.
50. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340(4):253-9.
51. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342(11):763-9.
52. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356(9227):385-90.
53. Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Burge D. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (ENBREL): results of a phase 3 multicenter clinical trial [abstract 226]. Arthritis Rheum 2001;44(Suppl 9):S90.
54. Gottlieb AB, Lowe NJ, Matheson RT, Lebsack ME. Efficacy of etanercept in patients with psoriasis [abstract]. Presented at the American Association of Dermatology. New York, August, 2002.
55. Gottlieb AB, Matheson RT, Lowe NJ, Zitnik RJ. Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol 2003; in press.
56. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39(12):2004-12.
57. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157(4):238-44.
58. Mease PJ, Goffe BS, Metz J, VanderStoep A, Burge DJ. Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis [abstract 2019]. Arthritis Rheum 2000;43(Suppl 9):S403.
59. Mease PJ, Goffe BS, Metz J, VanderStoep A, Burge DJ. ENBREL (etanercept) in patients with psoriatic arthritis and psoriasis [abstract THU0237]. Ann Rheum Dis 2001;60(Suppl 1):146.
60. Wanke LA, Gottlieb AB, Mease PJ, Kivitz AJ, Cohen SB, Burge DJ. Etanercept improves health-related quality of life in patients with psoriatic arthritis [abstract 97]. Arthritis Rheum 2002;46(Suppl 9):S76.
61. Ory P, Sharp JT, Salonen D, Rubenstein J, Mease PJ, Kivitz AJ, et al. Etanercept (ENBRELâ) inhibits radiographic progression in patients with psoriatic arthritis [abstract 442]. Arthritis Rheum 2002;46(Suppl 9):S196.
62. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337(15):1029-35.
63. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogez RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340(18):1398-405.
64. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
65. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344(8930):1105-10.
66. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Beys EM. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy [abstract 603]. Arthritis Rheum 2001;44(Suppl 9):S153.
67. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59(6):428-33.
68. Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61(3):207-12.
69. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002;46(6):886-91.
70. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357(9271): 1842-7.
71. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46(3): 755-65.
72. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47(5):506-12.
73. Antoni C, Kavanaugh A, Kirkham B, Burmeister G-R, Weisman M, Keystone E, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [abstract 985]. Arthritis Rheum 2002;46(Suppl 9):S381.
74. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359(9313): 1187-93.
75. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345(15):1098-104.
76. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44(9):1977-83.
77. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44(12):2862-9.
78. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46(10):2565-70.
79. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002;61(11):1031-2.
80. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med 2002;137(7): 625-6.
81. Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002;360(9333):646.
82. Ferraccioli GF, Assaloni R, Perin A. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002;360(9333):645.
83. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359(9306):579-80.
84. Keystone E, Kavanaugh AF, Sharp J, Hua Y, Teoh L, Fischkoff S, et al. Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [abstract 468]. Arthritis Rheum 2002;46(Suppl 9):S205.
85. McInnes IB, lllei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001;167:4075-82.
86. Reich K, Garbe C, Blaschke V, Maurer C, Middel P, Westphal G, et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type I inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway, and normalization of keratinocyte maturation. J Invest Dermatol 2001;116:319-29.
87. Asadullah K, Friedrich M, Hanneken S, Rohrbach C, Audring H, Vergopoulos AS, et al. Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol 2001;116:721-7.
88. Kraan MC, Van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, De Rie MA, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002;46(10):2776-84.
89. Gottlieb AB, Vaishnaw AK. Alefacept (Amevive) does not blunt primary or secondary immune responses [abstract 232]. Arthritis Rheum 2001;44(Suppl):S91.
90. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138(5):591-600.
91. Kaltwasser P, Nash P, Gladman D, Mease PJ. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis: results from the TOPAS study [abstract LB04]. Presented at the 66th Annual Scientific Meeting of the American College of Rheumatology. New Orleans, 2002.
92. Bloemendal A, Van der Zee R, Rutten VP, van Kooten PJ, Farine JC, van Eden W. Experimental immunization with anti-rheumatic bacterial extract OM-89 induced T cell responses to heat shock protein (hsp) 60 and hsp 70; modulation of peripheral immunological tolerance as its possible mode of action in the treatment of rheumatoid arthritis (RA). Clin Exp Immunol 1997;110:72-8.
93. Grantors K, Marke-Hermann E, de Keyser F, Khan MA, Veys EM, Yu DT. The cutting edge of spondyloarthropathy research in the millennium. Arthritis Rheum 2002;46:606-13.